Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) have received an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $98.00.

PTGX has been the subject of a number of research reports. HC Wainwright boosted their target price on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Weiss Ratings lowered Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, February 17th. Jefferies Financial Group increased their target price on Protagonist Therapeutics from $95.00 to $118.00 and gave the company a “buy” rating in a report on Monday, February 2nd. JPMorgan Chase & Co. raised their target price on Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, Citigroup boosted their price target on Protagonist Therapeutics from $98.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, December 8th.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $82.00, for a total transaction of $410,000.00. Following the completion of the sale, the insider directly owned 84,115 shares of the company’s stock, valued at approximately $6,897,430. This represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 4,068 shares of the stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $83.19, for a total transaction of $338,416.92. Following the completion of the transaction, the chief executive officer owned 574,505 shares in the company, valued at $47,793,070.95. The trade was a 0.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 203,167 shares of company stock valued at $16,889,199 in the last three months. Corporate insiders own 4.90% of the company’s stock.

Hedge Funds Weigh In On Protagonist Therapeutics

Institutional investors have recently bought and sold shares of the stock. Farallon Capital Management LLC grew its holdings in Protagonist Therapeutics by 0.4% during the third quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock valued at $411,601,000 after purchasing an additional 24,000 shares during the period. Vanguard Group Inc. lifted its position in shares of Protagonist Therapeutics by 27.2% during the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock valued at $472,832,000 after buying an additional 1,156,461 shares in the last quarter. BVF Inc. IL lifted its position in shares of Protagonist Therapeutics by 24.7% during the 2nd quarter. BVF Inc. IL now owns 3,211,041 shares of the company’s stock valued at $177,474,000 after buying an additional 636,026 shares in the last quarter. State Street Corp grew its stake in shares of Protagonist Therapeutics by 18.5% during the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock valued at $177,281,000 after acquiring an additional 500,924 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of Protagonist Therapeutics by 66.2% during the 4th quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock valued at $276,992,000 after acquiring an additional 1,262,977 shares during the period. 98.63% of the stock is owned by institutional investors.

Protagonist Therapeutics Stock Up 4.6%

Shares of PTGX stock opened at $86.59 on Thursday. The company has a 50 day moving average price of $84.20 and a 200-day moving average price of $76.18. Protagonist Therapeutics has a 52 week low of $33.70 and a 52 week high of $96.54. The firm has a market capitalization of $5.41 billion, a PE ratio of 139.66 and a beta of 2.26.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.